SCHEMBL22795083

SCHEMBL22795083

c1ccc(-c2ccc(C3CCCN(C4=NCCC4)C3)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.42
DRD1 P21728 1/20 0.42
DRD4 P21917 1/20 0.42
DRD5 P21918 1/20 0.42
DRD3 P35462 1/20 0.42
GBA1 P04062 1/20 0.42
HRH3 Q9Y5N1 1/20 0.40
NPC1 O15118 3/20 0.38
CYP1A2 P05177 3/20 0.38
CYP2C9 P11712 3/20 0.38
CYP2C19 P33261 3/20 0.38
RAB9A P51151 3/20 0.38
MAPT P10636 2/20 0.38
PDE3A Q14432 1/20 0.38
USP2 O75604 1/20 0.37
INMT O95050 1/20 0.37
GSK3B P49841 1/20 0.37
NR3C1 P04150 1/20 0.37
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22795444 1.00 DRD2 (0.42) DRD2DRD1DRD4DRD5DRD3
SCHEMBL22795431 1.00 DRD2 (0.42) DRD2DRD1DRD4DRD5DRD3
SCHEMBL22795049 0.80 GBA1 (0.43) DRD2DRD1DRD4DRD5DRD3
SCHEMBL22795549 0.80 GBA1 (0.43) DRD2DRD1DRD4DRD5DRD3
SCHEMBL22795028 0.80 GBA1 (0.43) DRD2DRD1DRD4DRD5DRD3
SCHEMBL22795445 0.75 ALDH1A1 (0.46) GBA1HRH3MAPTGSK3BROCK2
SCHEMBL22795449 0.75 ALDH1A1 (0.46) GBA1HRH3MAPTGSK3BROCK2
SCHEMBL29676576 0.75 ALDH1A1 (0.46) GBA1HRH3MAPTGSK3BROCK2
SCHEMBL22795084 0.75 ALDH1A1 (0.46) GBA1HRH3MAPTGSK3BROCK2
SCHEMBL9511532 0.73 SLC18A3 (0.39) DRD2DRD1DRD4DRD5DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12115154-B2 Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) SRX CARDIO, LLC (US) 2024-10-15 US disclosed
US-20220267269-A1 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO LLC (US) 2022-08-25 US disclosed
US-20220193058-A1 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO, LLC 2022-06-23 US disclosed
US-20220193058-A1 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO, LLC 2022-06-23 US disclosed
WO-2020252383-A2 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO, LLC (US) 2020-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193058-A1 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 DRD2 4779/4885DRD1 4846/4885DRD4 4721/4885
US-12115154-B2 Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) PCSK9, PCSK6, PCSK7 DRD2 4779/4885DRD1 4846/4885DRD4 4721/4885
US-20220267269-A1 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 DRD2 4779/4885DRD1 4846/4885DRD4 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.